Portfolio news Archives - Page 2 of 6

Versameb strengthens its Board of Directors

Versameb, transforming (m)RNA therapeutics to cure hard-to-treat and/or prevalent diseases, is pleased to announce the appointments of Hernán Levett, Dr Lily Geidelberg, Paul Korner, MD,…

Martyna Wroblewska12.07.2023

All Featured Portfolio news

Cimeio Therapeutics and Prime Medicine announce research collaboration

Our portfolio company, Cimeio Therapeutics, a biotechnology company that is reinventing cell therapy through its leadership in the emerging field of epitope shielding, and Prime…

Martyna Wroblewska22.06.2023

All Featured Portfolio news

Phialogics AG appoints Prof. Dr. Erich Schlick as Chairman of its Board of Directors

Phialogics AG has announced the appointment of Prof. Dr. Erich Schlick as Chairman of its Board of Directors. Erich was introduced to Phialogics by BaseLaunch…

Martyna Wroblewska12.05.2023

All Featured Portfolio news

Phialogics closed a €600k pre-seed financing round with HTGF

Our portfolio company, Phialogics - a preclinical stage company developing cell-type-specific immune checkpoint activators to prevent multi-organ failure in autoimmune diseases, closed a €600k pre-seed…

Martyna Wroblewska21.04.2023

All Featured Portfolio news

Engimmune Therapeutics appoints Dr. Lars Nieba as Chief Executive Officer

Engimmune Therapeutics, a Swiss biotech company developing novel T-cell receptor (TCR)-based therapeutics, has announced the appointment of Dr. Lars Nieba as Chief Executive Officer. Engimmune…

Martyna Wroblewska21.04.2023

All Portfolio news

BaseLaunch Portfolio has raised over half a billion dollars to date!

We are delighted to announce that our portfolio has blown past half a billion dollars raised to now collectively reach over $550M! Just the last…

Martyna Wroblewska13.04.2023

All Portfolio news

Alentis Therapeutics closes $105M funding round Led by Jeito Capital, Novo Holdings and RA Capital Management

Alentis Therapeutics is a thriving clinical-stage biotech company in Basel, Switzerland, developing breakthrough treatments for organ fibrosis and CLDN1 positive tumors. The company, lead by…

Martyna Wroblewska13.04.2023

All Portfolio news

FimmCyte joins BaseLaunch Portfolio

Endometriosis is a painful and debilitating condition that affects one in every ten women. Despite being a common health issue, there are currently limited treatment…

Martyna Wroblewska30.03.2023

All Featured Portfolio news

NXI Therapeutics Expands Management Team and Board Ahead of Next Growth Stage

NXI Therapeutics (formerly Nextimmune), the specialist biotech developing next generation immunosuppressive drugs for autoimmune diseases and organ transplantation, today announces that it has appointed Dr…

Martyna Wroblewska30.11.2022

All Portfolio news

Anaveon presents updated data from the Phase I/II study of ANV419 during the ESMO Congress 2022

Anaveon, a clinical-stage immuno-oncology company, announced updated clinical data from the ongoing Phase I/II study of ANV419 in patients with solid tumors, as well as…

Martyna Wroblewska27.09.2022

Portfolio news

Versameb strengthens its Board of Directors

Cimeio Therapeutics and Prime Medicine announce research collaboration

Phialogics AG appoints Prof. Dr. Erich Schlick as Chairman of its Board of Directors

Phialogics closed a €600k pre-seed financing round with HTGF

Engimmune Therapeutics appoints Dr. Lars Nieba as Chief Executive Officer

BaseLaunch Portfolio has raised over half a billion dollars to date!

Alentis Therapeutics closes $105M funding round Led by Jeito Capital, Novo Holdings and RA Capital Management

FimmCyte joins BaseLaunch Portfolio

NXI Therapeutics Expands Management Team and Board Ahead of Next Growth Stage

Anaveon presents updated data from the Phase I/II study of ANV419 during the ESMO Congress 2022

Useful links

Contact us

Sign up for our newsletter and event invitations

Follow us